Uncategorized
Glaukos Announces Submission of Pre-Market Approval Application for the iStent Inject® Trabecular Micro-Bypass
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass Stent. The iStent inject is designed to improve aqueous humor outflow into